Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Gilbert

Showing results (351-360 of 453) with videos related to

Pageof 46
Sort By:
Neuro-Oncology|February 12, 2011
Clinical trial end points for high-grade glioma: the evolving landscapeDavid A Reardon, Evanthia Galanis, John F DeGroot, et al.
International Journal of Radiation Oncology, Biology, Physics|January 17, 2025
Erratum to: Gondi V, Deshmukh S, Brown PD, et al. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001. Int J Radiat Oncol Biol Phys. 2023;117:571-580Vinai Gondi, Snehal Deshmukh, Paul D Brown, et al.
Oncotarget|May 10, 2015
Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapyHui Xu, Shervin Rahimpour, Cody L Nesvick, et al.
Neuro-Oncology|February 13, 2010
A multigene predictor of outcome in glioblastomaHoward Colman, Li Zhang, Erik P Sulman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2013
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical OncologyJyoti D Patel, Lada Krilov, Sylvia Adams, et al.
Neuro-Oncology Advances|July 10, 2020
MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironmentYu-Ting Su, Madison Butler, Meili Zhang, et al.
Journal of Neuropathology and Experimental Neurology|September 22, 2018
A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human GliomaJennifer W Koehler, Andrew D Miller, C Ryan Miller, et al.
Neuro-Oncology|February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Neuro-Oncology|March 14, 2020
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastomaVinay K Puduvalli, Jing Wu, Ying Yuan, et al.
Neuro-Oncology|May 28, 2025
Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cellsMorgan J Coombs, Tyrone Dowdy, Md Masud Alam, et al.
Pageof 46

Showing results (351-360 of 453) with videos related to

Sort By:
Pageof 46
Neuro-Oncology|February 12, 2011
Clinical trial end points for high-grade glioma: the evolving landscapeDavid A Reardon, Evanthia Galanis, John F DeGroot, et al.
International Journal of Radiation Oncology, Biology, Physics|January 17, 2025
Erratum to: Gondi V, Deshmukh S, Brown PD, et al. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001. Int J Radiat Oncol Biol Phys. 2023;117:571-580Vinai Gondi, Snehal Deshmukh, Paul D Brown, et al.
Oncotarget|May 10, 2015
Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapyHui Xu, Shervin Rahimpour, Cody L Nesvick, et al.
Neuro-Oncology|February 13, 2010
A multigene predictor of outcome in glioblastomaHoward Colman, Li Zhang, Erik P Sulman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2013
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical OncologyJyoti D Patel, Lada Krilov, Sylvia Adams, et al.
Neuro-Oncology Advances|July 10, 2020
MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironmentYu-Ting Su, Madison Butler, Meili Zhang, et al.
Journal of Neuropathology and Experimental Neurology|September 22, 2018
A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human GliomaJennifer W Koehler, Andrew D Miller, C Ryan Miller, et al.
Neuro-Oncology|February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Neuro-Oncology|March 14, 2020
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastomaVinay K Puduvalli, Jing Wu, Ying Yuan, et al.
Neuro-Oncology|May 28, 2025
Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cellsMorgan J Coombs, Tyrone Dowdy, Md Masud Alam, et al.
Pageof 46